(Total Views: 232)
Posted On: 03/14/2024 9:25:00 AM
Post# of 103408
$RSCI Company Initiates Plans to Build Oral Thin Film Manufacturing in the USA for Its Stop Smoking and Stop Vaping Products
https://www.prnewswire.com/news-releases/comp...88576.html
NEW YORK, March 14, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) is excited to announce significant milestones achieved in the year ending 2023 and its strategic plans moving forward. The company has conveyed to the Board its confidence in its role as a developer of innovative pharmaceutical products, positioning itself for sustained success over the next 36 months. Jason Cardiff, CEO of Redwood, has initiated discussions with the executive team to establish an oral thin film manufacturing hub in the United States. This initiative aims to make the company self-reliant by minimizing dependency on foreign-sourced pharmaceutical goods. In anticipation of its uplisting, Redwood is preparing to transition to the OTCQB platform, projected for April 2024.
2023 Company Highlights:
Completion and audit of the 2023 financials and management reports.
Submission of an application for NASDAQ listing, ensuring compliance with market requirements for free trading shares.
Successful navigation of the patent application process for Oral Thin Film Manufacturing and the active ingredient in its groundbreaking Smoking Cessation products without challenge.
Launch readiness of the fully developed product lineup, including TBX-FREE and TBX-VAPE-FREE.
Approval from the Brany Institute on Redwood's IRB for clinical study protocol.
Partnership with Jeeva Pharmaceutical for efficacy clinical testing at George Mason University.
https://www.prnewswire.com/news-releases/comp...88576.html
NEW YORK, March 14, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) is excited to announce significant milestones achieved in the year ending 2023 and its strategic plans moving forward. The company has conveyed to the Board its confidence in its role as a developer of innovative pharmaceutical products, positioning itself for sustained success over the next 36 months. Jason Cardiff, CEO of Redwood, has initiated discussions with the executive team to establish an oral thin film manufacturing hub in the United States. This initiative aims to make the company self-reliant by minimizing dependency on foreign-sourced pharmaceutical goods. In anticipation of its uplisting, Redwood is preparing to transition to the OTCQB platform, projected for April 2024.
2023 Company Highlights:
Completion and audit of the 2023 financials and management reports.
Submission of an application for NASDAQ listing, ensuring compliance with market requirements for free trading shares.
Successful navigation of the patent application process for Oral Thin Film Manufacturing and the active ingredient in its groundbreaking Smoking Cessation products without challenge.
Launch readiness of the fully developed product lineup, including TBX-FREE and TBX-VAPE-FREE.
Approval from the Brany Institute on Redwood's IRB for clinical study protocol.
Partnership with Jeeva Pharmaceutical for efficacy clinical testing at George Mason University.
(0)
(0)Scroll down for more posts ▼
